FDA alerts healthcare providers to counterfeit semaglutide (Ozempic) pens circulating in US supply chain
FDA issued a warning about counterfeit Ozempic (semaglutide; Novo Nordisk) injection pens identified in the US drug supply chain. The counterfeit units were labelled as 1 mg/dose but contained an unidentified substance. FDA urges pharmacies and patients to verify product by lot number, check for tamper-evident seal integrity, and source only from licensed wholesalers. No adverse events had been confirmed at time of issuance but patients experiencing unexpected glycaemic changes should contact their provider.
On 6 October 2026, FDA issued a safety alert warning healthcare providers and patients that counterfeit semaglutide pens labelled as Ozempic (semaglutide 1 mg/dose, Novo Nordisk) ↗ have been identified in the US drug supply chain. The counterfeit units were found in both retail pharmacy and direct-patient distribution channels. FDA urged providers to verify product authenticity using NDC verification and to report suspected counterfeits to FDA MedWatch ↗.
Why counterfeit semaglutide is dangerous
Counterfeit injectable products pose multiple serious risks: (1) unknown contents — analysed counterfeits have contained varying concentrations of semaglutide, insulin, or other peptides; (2) sterility failures — compounded or counterfeit injectables may carry bacterial contamination risk; (3) dose uncertainty — incorrect semaglutide concentrations can cause hypoglycaemia (if insulin-contaminated) or treatment failure (if underfilled). The surge in GLP-1 demand since 2023 has created a significant counterfeit market via grey-market online pharmacies. FDA maintains a dedicated counterfeit Ozempic alert page ↗.
How to identify authentic Ozempic pens
Authentic Ozempic pens (Novo Nordisk) carry an NDC 0169-4175-11 (3 mg/1.5 mL prefilled pen, 1 mg/dose) or equivalent NDC depending on pack size. Verify NDC against the FDA NDC directory ↗. Authentic pens have a Novo Nordisk holographic label, lot number and expiry laser-printed on the barrel, and match the carton label exactly. Counterfeit pens have been distributed through unlicensed online pharmacies and compounding operations — patients should only obtain semaglutide through their licensed pharmacy or healthcare provider. The NABP VIPPS programme ↗ verifies legitimate online pharmacies.
Reporting and clinical response
Any suspected counterfeit product should be quarantined and reported to (1) FDA MedWatch ↗ (online form or 1-800-FDA-1088); (2) the relevant state board of pharmacy; and (3) Novo Nordisk at 1-800-727-6500. Patients who may have received counterfeit pens should have blood glucose and HbA1c monitored, particularly if glycaemic control has unexpectedly worsened or if hypoglycaemic episodes have occurred. For GLP-1 safety and mechanism background, see the pharmacokinetics basics guide.
FAQ
How do I know if my batch is affected by this recall?
Check the lot number printed on the product label or carton against the specific lots listed in the official FDA recall notice ↗. If your lot number matches, do not use the product and contact your pharmacy or the recalling firm. You can also search the FDA Recalls database ↗ for the latest status.
What recall class is this?
FDA assigns recall classes: Class I (most serious — reasonable probability of serious adverse health consequences or death), Class II (may cause temporary or medically reversible adverse health consequences), or Class III (unlikely to cause adverse health consequences). The class is listed in the official notice ↗. For definitions see the FDA recall classification guide ↗.